- Home
- AUDC vs ATYR Comparison
AUDC vs ATYR Comparison
Compare AUDC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- ATYR
- Stock Information
- Founded
- AUDC 1992
- ATYR 2005
- Country
- AUDC Israel
- ATYR United States
- Employees
- AUDC N/A
- ATYR 59
- Industry
- AUDC Telecommunications Equipment
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AUDC Utilities
- ATYR Health Care
- Exchange
- AUDC Nasdaq
- ATYR Nasdaq
- Market Cap
- AUDC 282.4M
- ATYR 105.8M
- IPO Year
- AUDC 1999
- ATYR 2015
- Fundamental
- Price
- AUDC $10.18
- ATYR $1.03
- Analyst Decision
- AUDC Buy
- ATYR Buy
- Analyst Count
- AUDC 3
- ATYR 6
- Target Price
- AUDC $11.67
- ATYR $8.88
- AVG Volume (30 Days)
- AUDC 81.8K
- ATYR 15.6M
- Earning Date
- AUDC 11-05-2025
- ATYR 11-06-2025
- Dividend Yield
- AUDC 3.93%
- ATYR N/A
- EPS Growth
- AUDC 3.22
- ATYR N/A
- EPS
- AUDC 0.46
- ATYR N/A
- Revenue
- AUDC $243,249,000.00
- ATYR N/A
- Revenue This Year
- AUDC $2.52
- ATYR $420.85
- Revenue Next Year
- AUDC $1.74
- ATYR $1,919.44
- P/E Ratio
- AUDC $22.00
- ATYR N/A
- Revenue Growth
- AUDC N/A
- ATYR N/A
- 52 Week Low
- AUDC $7.70
- ATYR $0.97
- 52 Week High
- AUDC $12.72
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- AUDC 58.24
- ATYR 22.25
- Support Level
- AUDC $10.08
- ATYR $1.00
- Resistance Level
- AUDC $10.47
- ATYR $6.50
- Average True Range (ATR)
- AUDC 0.28
- ATYR 0.46
- MACD
- AUDC 0.08
- ATYR -0.51
- Stochastic Oscillator
- AUDC 76.98
- ATYR 1.01
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.